Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
1.140
+0.030 (2.70%)
At close: Aug 14, 2026, 4:00 PM EDT
1.130
-0.010 (-0.88%)
After-hours: Aug 14, 2026, 4:10 PM EDT

Marker Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
14.9216.0719.1915.1111.7842.35
Cash & Short-Term Investments
14.9216.0719.1915.1111.7842.35
Cash Growth
8.93%-16.28%27.01%28.26%-72.18%98.34%
Other Receivables
1.381.372.351.032.40
Receivables
1.381.372.351.032.40
Prepaid Expenses
0.420.660.480.991.852.48
Restricted Cash
0.720.97---1.15
Other Current Assets
----0.59-
Total Current Assets
17.4319.0722.0217.1316.6245.98
Property, Plant & Equipment
-----22.15
Other Long-Term Assets
----17.8-
Total Assets
17.4319.0722.0217.1334.4268.14
Accounts Payable
1.50.791.070.961.15.14
Accrued Expenses
1.210.32.191.911.273.33
Current Portion of Leases
-----0.62
Current Unearned Revenue
0.720.97---1.15
Other Current Liabilities
0.20.20.20.215.412.66
Total Current Liabilities
3.642.273.463.077.7812.9
Long-Term Leases
-----11.25
Other Long-Term Liabilities
----7.04-
Total Liabilities
3.642.273.463.0714.8224.15
Common Stock
0.020.020.010.010.010.01
Additional Paid-In Capital
476.14475.96465.56450.33447.64442.1
Retained Earnings
-462.36-459.18-447.02-436.29-428.05-398.12
Shareholders' Equity
13.816.818.5614.0519.643.99
Total Liabilities & Equity
17.4319.0722.0217.1334.4268.14
Total Debt
-----11.87
Net Cash (Debt)
14.9216.0719.1915.1111.7830.48
Net Cash Growth
8.93%-16.28%27.01%28.26%-61.35%235.15%
Net Cash Per Share
0.861.052.141.721.413.98
Filing Date Shares Outstanding
16.6716.6710.718.98.88.31
Total Common Shares Outstanding
16.6716.6710.718.898.418.31
Working Capital
13.816.818.5614.058.8433.08
Book Value Per Share
0.831.011.731.582.335.29
Tangible Book Value
13.816.818.5614.0519.643.99
Tangible Book Value Per Share
0.831.011.731.582.335.29
Machinery
-----9.66
Construction In Progress
-----2.23
Leasehold Improvements
-----3.17
SEC Filings: 10-K · 10-Q